Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
about
Studying epigenetic complexes and their inhibitors with the proteomics toolboxPLK-1 Targeted Inhibitors and Their Potential against TumorigenesisDiscovery and development of the Polo-like kinase inhibitor volasertib in cancer therapyThe bromodomain: from epigenome reader to druggable targetA Cell Biologist's Field Guide to Aurora Kinase InhibitorsRegulatory T Cell Modulation by CBP/EP300 Bromodomain InhibitionSelective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage ProgressionObserved bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2Comprehensive characterization of the Published Kinase Inhibitor SetERK5 and Cell Proliferation: Nuclear Localization Is What MattersTargeting bromodomains: epigenetic readers of lysine acetylationInhibition of BET bromodomains as a therapeutic strategy for cancer drug discoveryTargeting BET bromodomains for cancer treatmentGeneration of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia TherapyDrug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional SignaturesAn Epigenetic Compound Library Screen Identifies BET Inhibitors That Promote HSV-1 and -2 Replication by Bridging P-TEFb to Viral Gene Promoters through BRD4Predictions of Ligand Selectivity from Absolute Binding Free Energy CalculationsLeveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology.Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe MoleculesDrug Discovery Targeting Bromodomain-Containing Protein 4.Perspective on computational and structural aspects of kinase discovery from IPK2014Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.Structural basis for recognition of Emi2 by Polo-like kinase 1 and development of peptidomimetics blocking oocyte maturation and fertilization.Polypharmacology in Precision Oncology: Current Applications and Future ProspectsSynergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsChoose and Use Your Chemical Probe Wisely to Explore Cancer Biology.Fluorinated aromatic amino acids are sensitive 19F NMR probes for bromodomain-ligand interactions.Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision.Identification of Covalent Bromodomain Binders through DNA Display of Small Molecules.BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536The ins and outs of selective kinase inhibitor development.A Bead-Based Proximity Assay for BRD4 Ligand Discovery.Non-stoichiometric inhibition in integrated lead finding - a literature review.CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responsesMapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET.A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy
P2860
Q26738885-59F5FDC7-C125-4D33-A881-4DA1D458A23BQ26777811-1E11A40E-4FDF-4A12-8315-ED7635AAF32CQ26991736-E31FF7AC-ABB5-4B44-9A1E-7053F0E6D2AFQ26999935-415ECCD9-EF8E-4D25-9675-16819210C14AQ27308125-251EEDA0-6F17-4D43-AD41-129F2EE5C778Q27644651-EC68AFE9-9304-4C6B-8F7D-05A860FF9D1BQ27684429-E2553F3A-5499-4348-B20A-5BB3A6EFC241Q27696569-377620B0-3A0E-4077-A583-7B487995B1DFQ27702518-5E6F900E-BFAA-4268-A3EA-65CC2E67F0A7Q28078572-286237CA-62C9-47AA-893D-770136906DFCQ28238635-EDE05CF8-0A20-40EE-95DC-273BD09670A6Q28260105-D5AA86D9-4779-4E63-B79C-1A79FEA79049Q28263519-57E1F864-CD0C-42EE-9191-634C1CF0BB3FQ28269627-86EE5A97-611E-4C93-B2DE-459FCFAD580FQ28550603-E562D514-2167-49E7-B509-0203AC2E73BBQ28552849-CED8E20B-9C81-4ED5-9B92-A25921FFAB2DQ28818600-55D957CB-7101-4A1B-B747-66F4040B8205Q28821886-313FD4D9-BEA0-4EC1-A8E6-98FAB932EB0BQ28833420-C0311FFD-736F-41B9-ABA0-9998279C569DQ30352390-427F4BC2-DBAE-4E36-A727-DDCE676C0C63Q30373565-343FAFCA-9155-4632-BAE2-6A3364CF6423Q30384542-802293BC-48DB-4713-B92C-6518D0B5EBC5Q30667744-2BEAF1F5-0F42-40A1-B2FB-4F340BBB8593Q30846907-AEC67B38-9965-4070-8C44-B924EDB5EE2DQ33761796-C5228D37-081E-45E6-B570-1F38E6CC7C46Q33906319-140F6BC3-D58F-4D31-AE64-5D565F814D0DQ34756852-4A61450B-30EC-4A9A-AB54-69D590E709A3Q35016157-8E2A290F-0FF1-4B18-8345-975A1DFE3931Q35208927-51B3DD37-2B51-4860-A599-2E205F770680Q35577550-761471A5-51C2-4E75-96E9-E5C133B92D38Q35697342-FC5AB7D9-5E58-49E5-A951-723E9F288733Q35814547-8266DF66-FDF5-4A41-9FD8-8D47369B23A0Q35858434-2D5A6D05-C993-4D1D-8806-10B422E5BABDQ35865278-87E3D066-8481-457E-9EDE-E662DDA49DB0Q36008355-32BEA3E9-C224-4BEE-B48C-D1FF0E607B62Q36012341-7E2D8672-E3FB-4318-AD4D-E9108CEB4A3DQ36198013-41E0B62D-F071-4949-B87B-CDDFECDB23BAQ36290627-4A685BEE-A375-4B12-823D-9DFE44E10AF4Q36310219-BFA54E78-F39E-4082-81EB-345C7FFB2333Q36386336-51BE252F-A3BF-4D4E-8297-52DB9D9AE075
P2860
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@ast
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@en
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@nl
type
label
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@ast
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@en
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@nl
prefLabel
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@ast
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@en
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@nl
P2093
P2860
P50
P3181
P356
P1476
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
@en
P2093
Alison O'Mahony
Christopher Wells
Daniel K Treiber
Elisabeth A Lasater
Gabriel Pallares
Jeremy P Hunt
Lisa M Wodicka
Neil P Shah
Oleg Fedorov
Pietro Ciceri
P2507
P2860
P2888
P304
P3181
P356
10.1038/NCHEMBIO.1471
P577
2014-04-01T00:00:00Z
P5875
P6179
1037857835